Division of Medical Oncology, National Cancer Centre Singapore, Singapore
Division of Supportive and Palliative Care, National Cancer Centre Singapore, Singapore.
BMJ Open. 2022 Feb 7;12(2):e044661. doi: 10.1136/bmjopen-2020-044661.
The COVID-19 has caused significant mortality and morbidity across the globe. Patients with cancer are especially vulnerable given their immunocompromised state. We aimed to determine the proportion of COVID-19 patients with cancer, their severity and mortality outcomes through a systematic review and meta-analysis (MA).
Systematic review was performed through online databases, PubMed, Medline and Google Scholar, with keywords listed in the Methods section (1 November 2019-31 December 2020). Studies with clinical outcomes of at least 10 COVID-19 patients and at least one with a diagnosis of cancer were included. The studies for MA were assessed with PRISMA guidelines and appraised with Newcastle-Ottawa Scale. The data were pooled using a random-effects model using STATA software. The main outcomes were planned before data collection, including proportion of patients with cancer among COVID-19 populations, relative risk (RR) of severe outcomes and death of patients with cancer compared with general COVID-19 patients.
We identified 57 case series (63 413 patients), with 230 patients with cancer with individual patient data (IPD). We found that the pooled proportion of cancer among COVID-19 patients was 0.04 (95% CI 0.03 to 0.05, I=97.69%, p<0.001). The pooled RR of death was 1.44 (95% CI 1.19 to 1.76) between patients with cancer and the general population with COVID-19 infection. The pooled RR of severe outcome was 1.49 (95% CI 1.18 to 1.87) between cancer and general COVID-19 patients. The presence of lung cancer and stage IV cancer did not result in significantly increased RR of severe outcome. Among the available IPD, only age and gender were associated with severe outcomes.
Patients with cancer were at a higher risk of severe and death outcomes from COVID-19 infection as compared with general COVID-19 populations. Limitations of this study include publication bias. A collaborative effort is required for a more complete database.
COVID-19 在全球范围内造成了大量的死亡和发病。鉴于癌症患者的免疫功能低下,他们尤其容易受到影响。我们旨在通过系统评价和荟萃分析(MA)来确定 COVID-19 患者中患有癌症的患者比例、他们的严重程度和死亡率结果。
通过在线数据库、PubMed、Medline 和 Google Scholar 进行系统评价,关键词列于方法部分(2019 年 11 月 1 日至 2020 年 12 月 31 日)。纳入了至少有 10 例 COVID-19 患者且至少有 1 例癌症诊断的临床结局研究。MA 的研究采用 PRISMA 指南进行评估,并采用纽卡斯尔-渥太华量表进行评估。使用 STATA 软件通过随机效应模型对数据进行汇总。主要结局在数据收集之前计划,包括 COVID-19 人群中患有癌症的患者比例、癌症患者与普通 COVID-19 患者相比发生严重结局和死亡的相对风险(RR)。
我们确定了 57 项病例系列(63413 例患者),其中 230 例患者有癌症的个体患者数据(IPD)。我们发现,COVID-19 患者中癌症的总体比例为 0.04(95%CI 0.03 至 0.05,I=97.69%,p<0.001)。癌症患者与 COVID-19 感染普通人群相比,死亡的 RR 为 1.44(95%CI 1.19 至 1.76)。癌症患者与普通 COVID-19 患者相比,严重结局的 RR 为 1.49(95%CI 1.18 至 1.87)。肺癌和 IV 期癌症的存在并未导致严重结局的 RR 显著增加。在可用的 IPD 中,只有年龄和性别与严重结局相关。
与普通 COVID-19 人群相比,癌症患者感染 COVID-19 后出现严重和死亡结局的风险更高。本研究的局限性包括发表偏倚。需要协作努力以建立更完整的数据库。